会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明公开
    • 에제티밉의 제조방법 및 이에 사용되는 중간체
    • 制备EZETIMIBE的方法及其使用的中间体
    • KR1020100070305A
    • 2010-06-25
    • KR1020090125646
    • 2009-12-16
    • 한미약품 주식회사
    • 김기정김충한장지연김남두장영길이관순
    • C07D205/08C07D205/02
    • C07D205/08
    • PURPOSE: A method for manufacturing ezetimibe used for treatment or prevention of arteriosclerosis is provided to easily remove isomer and to obtain ezetimibe in high yield. CONSTITUTION: A manufacturing method of ezetimibe of chemical formula 1 comprises: a step of coupling a compound of chemical formula 2 with imine compound of chemical formula 6 under the presence of Lewis acid and base to obtain a compound of chemical formula 3; a step of cyclizing the compound of chemical formula 3 to obtain a compound of chemical formula 4; a step of asymmetry-reducing the compound of chemical formula 4 to obtain a compound of chemical formula 5; and a step of deprotecting the compound of chemical formula 5 under the presence of base.
    • 目的:提供用于治疗或预防动脉硬化的依泽替米贝的方法,以容易地除去异构体并以高产率得到依泽替米贝。 构成:化学式1的依泽替米贝的制造方法包括:在路易斯酸和碱存在下将化学式2的化合物与化学式6的亚胺化合物偶联的步骤,得到化学式3的化合物; 环化化学式3的化合物以获得化学式4的化合物的步骤; 不对称还原化学式4的化合物以获得化学式5的化合物的步骤; 在碱的存在下使化学式5的化合物脱保护的工序。
    • 5. 发明公开
    • 카르바페넴을 위한 알케닐 아제티디논 중간체 제조방법
    • 阿尔茨海默病中间体的制备
    • KR1020090101581A
    • 2009-09-29
    • KR1020080026799
    • 2008-03-24
    • 건국대학교 산학협력단
    • 김성훈강석원안현주김혜란김용훈
    • C07D205/08C07D205/12
    • Y02P20/55C07D205/08
    • PURPOSE: A method for preparing an alkenyl azetidinone intermediate for carbapenem is provided to easily synthesize effective 1β-methyl carbapenem compound with low price. CONSTITUTION: A method for preparing an alkenyl azetidinone intermediate for carbapenem comprises: a step of preparation with 4(R)-acetoxyazetidinone as a starting material; a step of performing crotylation under the presence of chiral ligand, transition metal, and Lewis acid; and a step of producing 4-(alk-2-enyl)-2-azetidinone of the chemical formula 1. The chiral ligand is selected from cinchonine, cinchonidin, quinine, quinidine, norephedrin, O-acetylquinine, and O-acetylquinidine. The transition metal is selected from zinc or indium. The Lewis acid is selected from AgCl, PdCl, AgOTf, InCl3, ZnBr2, and Sc(OTf)3.
    • 目的:提供一种制备碳青霉烯烯基氮杂环丁酮中间体的方法,以便以低价格轻松合成有效的1β-甲基碳青霉烯化合物。 构成:制备碳青霉烯烯基氮杂环丁酮中间体的方法包括:以4(R) - 乙酰氧基氮杂环丁酮为起始原料制备步骤; 在手性配体,过渡金属和路易斯酸的存在下进行溴化脱水的步骤; 以及制备化学式1的4-(烷-2-烯基)-2-氮杂环丁酮的步骤。手性配体选自辛可宁,辛可宁,奎宁,奎尼丁,去甲苯胺,O-乙酰奎宁和O-乙酰奎宁。 过渡金属选自锌或铟。 路易斯酸选自AgCl,PdCl,AgOTf,InCl3,ZnBr2和Sc(OTf)3。